Previous 10 | Next 10 |
2023-03-24 08:44:10 ET Regeneron ( NASDAQ: REGN ) continued to earn bullish views on Wall Street after the company, and its partner Sanofi ( SNY ) announced that asthma therapy Dupixent succeeded in a Phase 3 trial for adult smokers with chronic obstructive pulmonary disea...
2023-03-23 12:08:33 ET Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) were up as much as 8.2% on Thursday morning after the biotech company announced positive news on Thursday for a phase 3 trial for Dupixent (dupilumab) to treat patients with chronic obstructive pulmonary d...
2023-03-23 11:07:27 ET A combination of positive late-stage trial results for Dupixent (dupilumab) in chronic obstructive pulmonary disease (COPD) and a Street upgrade has propelled Regeneron Pharmaceuticals ( NASDAQ: REGN ) 7% higher in Thursday morning trading. Earli...
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo First and only biologic to show rapid and significant improvement in lung function (160 mL in FEV 1 ) compared to placebo (77 mL in...
2023-03-22 07:54:23 ET The U.S. Food and Drug Administration (FDA) approved the expanded use of Regeneron Pharmaceuticals' ( NASDAQ: REGN ) Evkeeza as an adjunct to other lipid-lowering therapies to treat children aged five to 11 years with homozygous familial hypercholeste...
Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol (LDL-C) 48% reduction in LDL-C from baseline at week 24 when Evkeeza was added to other lipi...
2023-03-21 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo Patients treated with Dupixent achieved rapid itch reduction as early a...
2023-03-19 15:47:43 ET Although the COVID-19 pandemic ended up being a cash cow for several pharma and biotech companies, many of them are seeking other treatments to focus on to replace revenue that is beginning to fade away. With their mRNA vaccines, Moderna ( NASDAQ: MRNA ...
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week TARRYTOWN, N.Y. and PARIS, Mar...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...